Article Citations

(Scroll Down for More)

Dong S, Hiam-Galvez KJ, Mowery CT, Herold KC, Gitelman SE, Esensten JH, Liu W, Lares AP, Leinbach AS, Lee M, Nguyen V, Tamaki SJ, Tamaki W, Tamaki CM, Mehdizadeh M, Putnam AL, Spitzer MH, Ye CJ, Tang Q, Bluestone JA (2021). The effect of low-dose IL-2 and Treg adoptive cell therapy in patients with type 1 diabetes. JCI Insight, 6(18). https://doi.org/10.1172/jci.insight.147474 PMID: 34324441. PMCID: PMC8492314.

‎

Dong S, Hiam-Galvez KJ, Mowery CT, Herold KC, Gitelman SE, Esensten JH, Liu W, Lares AP, Leinbach AS, Lee M, Nguyen V, Tamaki SJ, Tamaki W, Tamaki CM, Mehdizadeh M, Putnam AL, Spitzer MH, Ye CJ, Tang Q, Bluestone JA (2021). The effect of low-dose IL-2 and Treg adoptive cell therapy in patients with type 1 diabetes. JCI Insight, 6(18). https://doi.org/10.1172/jci.insight.147474 PMID: 34324441. PMCID: PMC8492314.

‎

Clinical TrialsCore FacilitiesLab ProtocolsPoliciesProposalsPublicationsTrialShareStrategic Plans

T1DM Immunotherapy Using Polyclonal Tregs + IL-2

Principal Investigator

Stephen Gitelman | University of California San Francisco | San Francisco, CA

Kevan Herold | Yale School of Medicine | New Haven, CT

Locations

UCSF School of Medicine: UCSF Diabetes Clinic | San Francisco,CA

Yale School of Medicine: Yale Diabetes Center | New Haven,CT

Study Code

ITN827AI

Study Status

Complete

Abstract

Qualification

[Clinicaltrials.gov][Study Website]

Articles

Dong S, Hiam-Galvez KJ, Mowery CT, Herold KC, Gitelman SE, Esensten JH, Liu W, Lares AP, Leinbach AS, Lee M, Nguyen V, Tamaki SJ, Tamaki W, Tamaki CM, Mehdizadeh M, Putnam AL, Spitzer MH, Ye CJ, Tang Q, Bluestone JA (2021). The effect of low-dose IL-2 and Treg adoptive cell therapy in patients with type 1 diabetes. JCI Insight, 6(18). https://doi.org/10.1172/jci.insight.147474 PMID: 34324441. PMCID: PMC8492314.

PMID: 

34324441

,‎ 

PMCID: 

PMC8492314

,‎ 

PubMed

,‎ 

Reprint
Download Citations